Source: PHARMAC, 28 July 2016
PHARMAC has today announced changes to funded vaccines, which
will benefit an extra 100,000 people, says PHARMAC Director of
Operations Sarah Fitt.
The changes include:
- From 1 January 2017:
- The human papillomavirus (HPV) vaccine will be available for
all children and adults up to the age of 26 years, and boys will
now be included in the HPV school vaccination programme. The HPV
vaccine itself will also change to cover more strains of the virus,
in fewer doses.
- From 1 July 2017:
- The varicella (chickenpox) vaccine will be funded for all
children as a part of the childhood immunisation schedule
- The pneumococcal vaccine will change from a 13 strain to a 10
- The rotavirus vaccine will change brand and move to a two-dose
- The measles, mumps and rubella (MMR) and haemophilus influenza
type b (Hib) vaccines will move to new brands.
"Preventing illnesses through vaccinations is important to the
health of all New Zealanders, as they don't just help the people
receiving them, but also their family and whanau, and wider
society," says Ms Fitt.
"It's important that PHARMAC responds to the changing nature of
preventable illness and the evolution in the science of
vaccinations. We work closely with our expert clinical advisers as
well as our health sector partners to make sure we target the right
areas of need.
"The changes have been made possible following constructive
negotiations with suppliers that have created significant savings,
and have allowed wider access to vaccines while reducing the
overall cost to New Zealand."
The changes include a change from a 13 strain to a 10 strain
version of the pneumococcal vaccine.
"PHARMAC received a lot of feedback from our health sector
partners regarding the changes to the pneumococcal vaccine," says
"Our expert clinical advisers support the move to Synflorix, a
10 strain version of the pneumococcal vaccine and have said that
it's suitable for New Zealand. Other versions of the vaccine,
including the 13 strain and 23 strain will remain fully funded for
high risk patients.
"Through a focus on the best overall package of vaccines to
fund, this change has also helped provide flexibility to widen
access to the HPV and varicella vaccines, which will provide
significant health benefits to New Zealand.
In addition to the further summary information below, more
information can be found in the notification document, available on